Pacific Biosciences Of California (PACB) Amortization of Deferred Charges (2013 - 2026)

Pacific Biosciences Of California's Amortization of Deferred Charges history runs 14 years deep, the most recent figure standing at $849000.0 for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 32.51% year-over-year to $849000.0; the TTM figure through Mar 2026 stood at $3.6 million (down 68.98% YoY), while the FY2025 annual figure was $4.0 million, down 67.31% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $849000.0, down from $894000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $5.1 million in Q3 2024, with the low at $154000.0 in Q2 2022.
• The 5-year median for Amortization of Deferred Charges is $1.3 million (2025), against an average of $1.5 million.
• The sharpest annual moves came in 2024 and 2025: Amortization of Deferred Charges surged 2440.0% in 2024, then sank 81.78% in 2025.
• Pacific Biosciences Of California's Amortization of Deferred Charges stood at $1.8 million in 2022, then advanced by 5.47% to $1.9 million in 2023, then tumbled by 32.99% to $1.3 million in 2024, then decreased by 28.65% to $894000.0 in 2025, then fell by 5.03% to $849000.0 in 2026.
• Business Quant data shows PACB's Amortization of Deferred Charges at $849000.0 in Q1 2026, $894000.0 in Q4 2025, and $921000.0 in Q3 2025.